Browse All

Current Filters

CLEAR FILTER x

TITLE

Top-line Results From MaGic, a Phase Two Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis

Rapid and Sustained Efficacy of Subcutaneously Administered Cemdisiran Without Complete Complement Blockade in Patients with Generalized Myasthenia Gravis (gMG): Primary Efficacy and Safety Results from the Phase Three NIMBLE Trial

Response to Rozanolixizumab Across Treatment Cycles in Patients With Generalized Myasthenia Gravis: A Post Hoc Analysis of Final Pooled Phase Three Data